GAIA Society for Self-Sufficiency DE EN

Health & Nutrition

Vitamin C in DMSO effective against skin cancer

Vitamin C in DMSO effective against skin cancer
Dr. Peter F. Mayer, tkp.at

An open clinical study using a simple 30 per cent ascorbic acid solution in DMSO reports complete histological clearance in more than half of the treated lesions of an early skin cancer.

The results fit the mechanism we have already described on TKP several times: highly concentrated vitamin C acts as a pro-oxidant in tumour tissue and produces hydrogen peroxide (H₂O₂), which preferentially damages diseased cells. Nicolas Hulscher summarised the work on 28 September 2026 on The Focal Points. The underlying preprint study by Patricia Miller, Jon Ward, Michael Morgan and Briant Burke was published on 16 October 2025 on medRxiv (DOI: 10.1101/2025.10.13.25337920). It examined 17 patients with a total of 27 biopsy-confirmed squamous cell carcinomas in situ (SCCIS), that is, carcinomas confined to the epidermis.

Twice daily for twelve weeks, the participants applied a 30 per cent ascorbic acid solution in 95 per cent DMSO and 5 per cent distilled water directly to the lesions with a small brush. DMSO serves here primarily as a penetration enhancer: it temporarily alters the lipid structure of the skin barrier and allows the water-soluble vitamin C to reach the tissue. The authors point out that DMSO itself may have biological effects, but they regard it mainly as a carrier.

After twelve weeks, a repeat biopsy was carried out. The key results:

  • In 15 of 27 lesions (56 per cent), no carcinoma was histologically detectable any more.
  • 44 per cent of the lesions shrank by more than 85 per cent.
  • The mean lesion area fell by 71 per cent, from 1.06 cm² to 0.30 cm².
  • Only two lesions (7 per cent) did not respond.
  • 16 of 17 patients (94 per cent) were able to avoid surgical excision.
  • The treatment was well tolerated; nobody discontinued it because of side effects.

Remaining changes often corresponded merely to actinic atypia without carcinoma and could subsequently be treated with cryotherapy. The authors see in this a possible non-invasive alternative to surgery and call for larger, controlled studies.

Known mechanisms of action

The proposed mechanism of action matches what was already set out on TKP in 2024 and at the beginning of 2026. The article “How vitamin C and its metabolite H2O2 sustain life” described how ascorbic acid, at high local concentrations, forms hydrogen peroxide as a pro-oxidant.

Tumour cells often have lower amounts of catalase and other antioxidant enzymes and are therefore more vulnerable to oxidative stress. Healthy tissue breaks down H₂O₂ more quickly. The same relationship is at the heart of the article “Vitamin C used correctly cures cancer” of 31 January 2026: plasma concentrations above about 13 mmol/l, reached intravenously, generate extracellular H₂O₂, which selectively damages malignant cells, whereas oral doses do not reach this threshold. The topical formulation with DMSO aims to produce precisely such high concentrations locally within the skin tumour, without requiring a systemic infusion.

An earlier, peer-reviewed randomised study by the same research group supports this direction. In 2022, in Biomedicine & Pharmacotherapy (DOI: 10.1016/j.biopha.2022.112710), Burke and Bailie compared the same 30 per cent ascorbic acid–DMSO solution with 5 per cent imiquimod in basal cell carcinomas. After eight weeks, 13 of 15 lesions (86.7 per cent) in the vitamin C group showed complete histological resolution, compared with 8 of 14 (57.1 per cent) under imiquimod. The difference was statistically significant; in the long term, no hypopigmentation occurred under vitamin C, whereas it was frequent under imiquimod.

The new SCCIS study is methodologically weaker: it is open-label, single-arm, small and so far available only as a preprint. There is no control group, and the contribution of DMSO alone is not isolated. Nevertheless, the histological determination of the endpoint is a clear advantage over purely clinical assessments.

Oncology in the service of the pharmaceutical industry

The results fit into a pattern that established oncology has largely ignored since the fundamental studies and scientific findings of Nobel laureate in chemistry Linus Pauling and Ewan Cameron.

High-dose vitamin C is not patentable, is cheap and acts via a physiological metabolite. Whether topical application becomes a reliable first-line treatment for superficial non-melanoma skin cancers must be clarified by larger randomised studies. However, the available data give a concrete reason to keep examining the H₂O₂ mechanism, not only with intravenous administration but also locally.

The efficacy and mechanisms of action of the aprotic polar solvent DMSO have likewise been known for decades and documented thousands of times over. DMSO is just as cheap and just as unpatentable as vitamin C, so the combination is even less welcome than either of the two alone.

More information on DMSO

There is a wealth of knowledge in a whole series of books (all in German):

DMSO and mixtures can be found in specialist drugstores, pharmacies (which also make up mixtures to order, for example for eye drops) or through mail order:

And there is even more on DMSO in TKP:

On protocols for use:

DMSO for various areas of application:

Links to earlier TKP articles on the subject can be found below 👇


Our work is funded by donations – we ask for your support.

Follow TKP on Telegram or GETTR and subscribe to our newsletter.



This article first appeared in German on tkp.at – with kind permission of Dr. Peter F. Mayer.
Cover image: HeungSoon / Pixabay

Notes on content provided by authors

Comments

Loading comments …

Become a member to comment publicly. GAIA members write comments in the members' portal — under their nickname, visible to everyone.

Become a member Already a member? Comment in the portal →

Translate

Machine translation by Google Translate. The page address is only sent to Google once you click — privacy.